Scientist Solutions: International Life Science Community By Scientists For Scientists

Thanks to our sponsors who make this site possible

    

Scientist-Solutions

 



Google+

At Scientist Solutions we cherish our role as a trusted source of information for scientists.  We hope that our newly designed site will make it easier than ever for you to access everything we have to offer.   Things may have moved around a little, but rest assured that all the features you enjoyed on our old site (the forums, the protocols, the events, my bench space, blogs)  are still here.  

Our Discussion Forums

Scientist Solutions began as a discussion board for life scientists and that is still one of our core offerings.   If you are looking for the discussion forums, please click "The Forums"  from the navigation bar above or click here.

Protocols and SciEvents

Always on the look out for new ways to help scientists to help each other,  Scientist Solutions introduced a new protocols section and an events section to our site in the past year.   Both have been very popular.   If you haven't yet discovered these listings, we invite you to do so now. 

Our Protocol Finder provides an easily searchable database of protocols that you can use both to find a protocol you need or to share the protocols that you rely on.  Just click "Protocol Finder" from the navigation bar above, or click here.

Our SciEvents section is setting out to be the most comprehensive listing of conferences, seminars, classes and webinars for life scientists on the web.   Search events listings by date, topic or type of event.    You are most welcome to add your own events to our listing too.   Just click SciEvents from the navigation bar above, or click here.

My Bench SpaceMembership Management

Are you looking for how to log in or wondering what happened to your bench space?     On our new site, we have made it much easier for you to manage your account and profile.   After logging in (note that the log in area has moved down the page),  you will see your new member status panel on the right hand side of the home page and every page.    Look here for an overview of your member information and find easy access to your newly remodeled My Bench Space, where you'll be able to edit your account information and preferences and manage your public profile.   Just click "Go to My Bench Space" from your member status panel or click here.

Blogging

Notice that featured blogs are now presented on the home page just below this article.   To read all blogs, just click the "view more" link below the featured blogs.   To create your own blog, go to your My Bench Space pages and click on the "blogs" tab.  To get to My Bench Space, log in then click the "Go to My Bench Space" link in your member status panel (see above) or just click here

Give us your feedback

We understand that it takes a little adjustment time to get used to a new design.  We apologize for any temporary confusion, but hope that once you've familiarized yourself with the new design and features you will be very pleased.   Either way, we would love to hear what you think.  Please share your opinion by clicking the 'contact us'  link at the top right of any page and send us a note or click here.




Latest Member Blogs

Member
Total Posts: 1
9/13/2016
02:55AM
Member
Total Posts: 1
12/18/2015
02:17PM
Member
Total Posts: 1
12/6/2015
02:00PM




Science News Feeds

Click a source to select it and see feeds below

BioScience News
Pharmaceutical News
Biotechnology News
Today's Science News
This Week in Science
Science (Editorial)
Science Now
Nextwave
New York Times
BBC
Bioscreening
Journals
Journal of Biology
Nature
European Journal of Cell Biology
Virology Journal
Science
PNAS
Magazines
New Scientist
The Scientist
Pharmaceutical Business Review
Life Sciences World
Science News

Biotechnology - Google News
Google News
Enanta Pharmaceuticals Inc (ENTA) Lowered to Sell at Zacks Investment Research - Sports Perspectives

Enanta Pharmaceuticals Inc (ENTA) Lowered to Sell at Zacks Investment Research
Sports Perspectives
Zacks Investment Research lowered shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) from a hold rating to a sell rating in a research report released on Friday, May 12th. According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company.

and more »
Cantor Fitzgerald Analysts Give Cidara Therapeutics Inc (CDTX) a $11.00 Price Target - The Momentous News

Cantor Fitzgerald Analysts Give Cidara Therapeutics Inc (CDTX) a $11.00 Price Target
The Momentous News
The firm currently has a buy rating on the biotechnology company's stock. Several other equities research analysts have also recently commented on CDTX. Wedbush reissued an outperform rating and issued a $22.00 target price (up from $13.00) on shares ...

and more »
Kamada Ltd (KMDA) Earns "Buy" Rating from Jefferies Group LLC - Sports Perspectives

Kamada Ltd (KMDA) Earns "Buy" Rating from Jefferies Group LLC
Sports Perspectives
They currently have a $9.00 price objective on the biotechnology company's stock. Jefferies Group LLC's price objective would suggest a potential upside of 25.87% from the company's current price. Other research analysts have also issued reports about ...

and more »
Prana Biotechnology Limited (PRAN) Earns Media Impact Score of -0.39 - Transcript Daily

Transcript Daily

Prana Biotechnology Limited (PRAN) Earns Media Impact Score of -0.39
Transcript Daily
Prana Biotechnology Limited logo News headlines about Prana Biotechnology Limited (NASDAQ:PRAN) have trended negative this week, according to Alpha One. The research group, a unit of Accern, rates the sentiment of press coverage by analyzing more ...

Kamada Ltd (KMDA) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS - The Cerbat Gem

The Cerbat Gem

Kamada Ltd (KMDA) Issues Quarterly Earnings Results, Misses Estimates By $0.08 EPS
The Cerbat Gem
Kamada logo Kamada Ltd (NASDAQ:KMDA) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.08. Kamada had a ...

and more »
Kamada Ltd (KMDA) Announces Earnings Results - Chaffey Breeze

Chaffey Breeze

Kamada Ltd (KMDA) Announces Earnings Results
Chaffey Breeze
Kamada logo Kamada Ltd (NASDAQ:KMDA) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.08.

and more »
Amyris Inc (AMRS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - The Cerbat Gem

Amyris Inc (AMRS) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS
The Cerbat Gem
Amyris logo Amyris Inc (NASDAQ:AMRS) posted its earnings results on Monday. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The company had revenue of $13 ...

and more »
Acadian Asset Management LLC Sells 21187 Shares of NanoString Technologies Inc (NSTG) - The Cerbat Gem

Acadian Asset Management LLC Sells 21187 Shares of NanoString Technologies Inc (NSTG)
The Cerbat Gem
The fund owned 40,065 shares of the biotechnology company's stock after selling 21,187 shares during the period. Acadian Asset Management LLC owned 0.19% of NanoString Technologies worth $796,000 as of its most recent filing with the SEC.

and more »
Glen Harbor Capital Management LLC Has $188000 Stake in BIO-TECHNE Corp (TECH) - Chaffey Breeze

Glen Harbor Capital Management LLC Has $188000 Stake in BIO-TECHNE Corp (TECH)
Chaffey Breeze
The firm owned 1,848 shares of the biotechnology company's stock after buying an additional 168 shares during the period. Glen Harbor Capital Management LLC's holdings in BIO-TECHNE Corp were worth $188,000 as of its most recent filing with the SEC.

and more »
Bioline RX Ltd (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts - Sports Perspectives

Bioline RX Ltd (BLRX) Given a $4.00 Price Target by HC Wainwright Analysts
Sports Perspectives
The brokerage currently has a buy rating on the biotechnology company's stock. Several other equities research analysts have also commented on BLRX. Rodman & Renshaw started coverage on Bioline RX in a research note on Monday, February 13th.

and more »